Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AZ and Biocompatibles enter GLP-1 alliance; later terminated

Executive Summary

AstraZeneca and drug delivery device firm Biocompatibles International PLC have entered into an agreement that gives AZ an exclusive option to license a new discovery-stage glucagon-like peptide (GLP-1; a naturally occurring hormone that stimulates the pancreas to produce insulin) analog and its patents for Type II diabetes and obesity.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register